Fatigue

Spring Break Water Safety Tips for Kids and Families

Retrieved on: 
Monday, March 4, 2024

Families are kicking off the spring season with spring break trips, traveling from across the country to warmer weather.

Key Points: 
  • Families are kicking off the spring season with spring break trips, traveling from across the country to warmer weather.
  • As parents tackle their packing and planning to-do lists, Big Blue Swim School reminds all caregivers to check off reviewing water and swim safety tips for the whole family.
  • Big Blue Swim School offers the following tips to make sure that families remain safe around the water this spring break:
    Remember, lifeguards are not babysitters.
  • Even with this important safety system in place at pools or beaches, adult supervision around water is essential.

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI

Retrieved on: 
Thursday, February 29, 2024

Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a group of rare, chronic and progressive blood cancers.

Key Points: 
  • Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a group of rare, chronic and progressive blood cancers.
  • View the full release here: https://www.businesswire.com/news/home/20240229692531/en/
    The Unseen Journey highlights the stories of people living with MPNs who were asked to describe their symptoms and how they impact their lives in their own words.
  • As each patient described their symptoms and experiences, generative AI tools transformed their words into images that visually depict the patient’s most burdensome symptoms.
  • It is important for MPN patients to track their symptoms on a regular basis to help inform conversations with their health care provider.

Western Express selects Motive to take its safety culture and driver training to new heights

Retrieved on: 
Wednesday, February 28, 2024

Western Express will utilize Motive’s AI Dashcam to prevent more safety events, coach drivers, and gain end-to-end visibility into its fleet operations.

Key Points: 
  • Western Express will utilize Motive’s AI Dashcam to prevent more safety events, coach drivers, and gain end-to-end visibility into its fleet operations.
  • As a leading U.S. carrier, Western Express in Nashville aimed to enhance its premier safety program.
  • By adopting Motive's AI Dashcam, Western Express gains AI-driven insights and comprehensive visibility, enabling better driver coaching and safety monitoring on a unified platform to proactively address these new challenges.
  • “To partner with a company like Western Express to enhance the implementation of their core values is a privilege.

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Retrieved on: 
Friday, February 23, 2024

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.

Key Points: 
  • AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.
  • Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA).
  • Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
  • A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON).

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

Retrieved on: 
Tuesday, February 20, 2024

Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.

Key Points: 
  • Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.
  • The total round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
  • The funding will advance the Company’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
  • Pacyna continued, “Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients.

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart

Retrieved on: 
Tuesday, February 20, 2024

BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.

Key Points: 
  • BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.
  • View the full release here: https://www.businesswire.com/news/home/20240220429887/en/
    BiVACOR® Total Artificial Heart (TAH) in Surgeon's Hands (Photo: Business Wire)
    Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACOR.
  • The award will support clinical work of the BiVACOR Total Artificial Heart (TAH) and begin development for the integration of wireless power sources for the device.
  • “There is a huge gap between available treatment options and the number of patients with severe heart failure.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Retrieved on: 
Friday, March 8, 2024

"This patient population has a higher risk of cardiovascular death, heart attack and stroke.

Key Points: 
  • "This patient population has a higher risk of cardiovascular death, heart attack and stroke.
  • Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
  • Obesity or overweight affect approximately 70% of American adults.
  • Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.

Hexcal Introduces Revolutionary High-Tech Workspace Solution

Retrieved on: 
Friday, March 8, 2024

NEW YORK, March 8, 2024 /PRNewswire/ -- Hexcal, a trailblazer in innovative workspace solutions, present a comprehensive suite of premium products designed to elevate peeple's workspace and redefine desk setup experience.

Key Points: 
  • Introducing a whole desk setup solution from Hexcal, offering ultimate workspace experience
    NEW YORK, March 8, 2024 /PRNewswire/ -- Hexcal , a trailblazer in innovative workspace solutions, present a comprehensive suite of premium products designed to elevate peeple's workspace and redefine desk setup experience.
  • In 2022, Hexcal launched Hexcal Studio , which has been a valuable asset for professional users in their daily work.
  • In addition to Hexcal Studio , Hexcal continues to provide premium products for desk setup enthusiasts.
  • Elevate your workspace with Hexcal, where every detail is designed to inspire and enhance your daily work routine.

3D Printing High-Performance Plastics Market to Reach $520.0 Million by 2028: BCC Research

Retrieved on: 
Friday, March 8, 2024

BOSTON, March 8, 2024 /PRNewswire/ -- "According to the latest BCC Research study, the demand for Global 3D Printing High-Performance Plastics Market is estimated to increase from $163.6 million in 2022 to reach $520.0 million by 2028, at a compound annual growth rate (CAGR) of 21.4% from 2022 through 2028."

Key Points: 
  • BOSTON, March 8, 2024 /PRNewswire/ -- "According to the latest BCC Research study, the demand for Global 3D Printing High-Performance Plastics Market is estimated to increase from $163.6 million in 2022 to reach $520.0 million by 2028, at a compound annual growth rate (CAGR) of 21.4% from 2022 through 2028."
  • This comprehensive report focuses specifically on high-performance plastics within the expansive 3D printing industry, highlighting key materials such as polyamide, polyetherimide, polyetheretherketone, polyetherketoneketone, polyvinylidene difluoride, and polyphenylsulfone.
  • The forecasted revenue projections from 2022 to 2028 encompass each type, technology, end-user, and regional segment, offering a comprehensive outlook on the evolving landscape of the 3D printing high-performance plastics market.
  • The intersection of digitalization, robotics, and the growing demand for personalized, point-of-care medical solutions is fueling a surge in high-performance plastics (HPP) adoption in 3D printing.

Inequalities in the face of cardiovascular risk: women the No. 1 victims

Retrieved on: 
Thursday, March 7, 2024

BOSTON, March 7, 2024 /PRNewswire/ -- Cardiovascular disease kills one women every 33 seconds in the USA10. Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women. To help reduce this excess mortality, Withings is committed to raising awareness via an exclusive survey, and providing the means to tackle their main cause: hypertension, which accounts for the majority of cardiovascular deaths.12

Key Points: 
  • Inequalities also affect health, particularly cardiovascular health: they lead to under-diagnosis and poorer care for women, resulting in avoidable excess mortality.
  • Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women.
  • Yet 50% of women are unaware of their cardiovascular risk.13
    45.9% of American women surveyed by Withings admit to putting their loved ones' health before their own.
  • Withings and cardiovascular monitoring in women: the need for a real-life, longitudinal approach
    Monitoring cardiovascular health and hypertension involves tracking a range of biomarkers.